Pharmacological treatment of obesity in adults in Norway 2004–2022
Aims To describe trends in the use of anti‐obesity drugs in Norway during the period 2004–2022. Materials and Methods We assessed the annual utilization of any available drug indicated for obesity recorded in the nationwide Norwegian Prescribed Drug Register for adults (age 18–79 years) from 1 Janua...
Gespeichert in:
| Veröffentlicht in: | Diabetes, obesity & metabolism obesity & metabolism, 2024-06, Vol.26 (6), p.2102-2110 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 2110 |
|---|---|
| container_issue | 6 |
| container_start_page | 2102 |
| container_title | Diabetes, obesity & metabolism |
| container_volume | 26 |
| creator | Ruiz, Paz Lopez‐Doriga Karlstad, Øystein Nøkleby, Kjersti Slåtsve, Kristina Gulseth, Hanne L. Meyer, Haakon E. Sveen, Kari Anne Qvigstad, Elisabeth Furu, Kari |
| description | Aims
To describe trends in the use of anti‐obesity drugs in Norway during the period 2004–2022.
Materials and Methods
We assessed the annual utilization of any available drug indicated for obesity recorded in the nationwide Norwegian Prescribed Drug Register for adults (age 18–79 years) from 1 January 2004 to 31 December 2022. Prevalence was stratified by sex and age group (18–29 years and 10‐year age groups thereafter). Additional analyses were performed in individuals initiating treatment with an anti‐obesity drug and on the cost of the anti‐obesity drugs since 2017.
Results
The prevalence of anti‐obesity drug use decreased from 2009, when sibutramine and rimonabant were withdrawn from the market, and increased again after the approval of bupropion‐naltrexone in 2017 and liraglutide in 2018. The use of the peripheral‐acting anti‐obesity drug orlistat decreased from 2004. In 2022, 1.04% of the adult Norwegian population (72.8% women) filled at least one prescription of bupropion‐naltrexone, 0.91% used liraglutide (Saxenda; 74.2% women), and semaglutide without reimbursement was used by 0.68% (76.7% women). The prevalence increased with age, peaking in the age group 50 to 59 years, and decreased in older age groups. From 2017 to 2022, 2.8% of the adult residents initiated treatment with an anti‐obesity drug. The total sale of those drugs increased from 1.1 million euros in 2017 to 91.8 million euros in 2022.
Conclusions
The use of anti‐obesity drugs in Norway has increased substantially in recent years, especially among women aged 40 to 59 years. Changes in availability and reimbursement have influenced the use of these drugs in recent years. |
| doi_str_mv | 10.1111/dom.15515 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_crist</sourceid><recordid>TN_cdi_cristin_nora_10852_111243</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2933460160</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4135-9dc5d6635ab20eb9b742cd0fc4aa44959a320cf74bd40431bfefa095f03a00243</originalsourceid><addsrcrecordid>eNp1kLtOxDAQRS0E4rFQ8AMoEg0U2R2_krhEy1MClgJqy3EcCEpisBOhdPwDf8iX4N0ABRLTeIqjc8cXoX0MUxxmVthmijnHfA1tY5bQGFOSrK92EmcCyBba8f4ZABjN0k20RTOGBcOwjU7vnpRrlLa1fay0qqPOGdU1pu0iW0Y2N77qhqhqI1X0deeX2611b2qISLB9vn8QIGQXbZSq9mbv-52gh_Oz-_llfL24uJqfXMeaYcpjUWheJAnlKidgcpGnjOgCSs2UYkxwoSgBXaYsL1i4FOelKRUIXgJVAITRCYpGr3aV76pWttYpiSHjRIYeAhGQoxF5cfa1N76TTeW1qWvVGtt7SQSlLAGcQEAP_6DPtndt-ICkwHGacZqKQB3_ZFrvnSnli6sa5YaQuwzFMrQvV-0H9uDb2OeNKX7Jn7oDMBuBt6o2w_8mebq4GZVfRI-KiQ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3051785379</pqid></control><display><type>article</type><title>Pharmacological treatment of obesity in adults in Norway 2004–2022</title><source>MEDLINE</source><source>NORA - Norwegian Open Research Archives</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Ruiz, Paz Lopez‐Doriga ; Karlstad, Øystein ; Nøkleby, Kjersti ; Slåtsve, Kristina ; Gulseth, Hanne L. ; Meyer, Haakon E. ; Sveen, Kari Anne ; Qvigstad, Elisabeth ; Furu, Kari</creator><creatorcontrib>Ruiz, Paz Lopez‐Doriga ; Karlstad, Øystein ; Nøkleby, Kjersti ; Slåtsve, Kristina ; Gulseth, Hanne L. ; Meyer, Haakon E. ; Sveen, Kari Anne ; Qvigstad, Elisabeth ; Furu, Kari</creatorcontrib><description>Aims
To describe trends in the use of anti‐obesity drugs in Norway during the period 2004–2022.
Materials and Methods
We assessed the annual utilization of any available drug indicated for obesity recorded in the nationwide Norwegian Prescribed Drug Register for adults (age 18–79 years) from 1 January 2004 to 31 December 2022. Prevalence was stratified by sex and age group (18–29 years and 10‐year age groups thereafter). Additional analyses were performed in individuals initiating treatment with an anti‐obesity drug and on the cost of the anti‐obesity drugs since 2017.
Results
The prevalence of anti‐obesity drug use decreased from 2009, when sibutramine and rimonabant were withdrawn from the market, and increased again after the approval of bupropion‐naltrexone in 2017 and liraglutide in 2018. The use of the peripheral‐acting anti‐obesity drug orlistat decreased from 2004. In 2022, 1.04% of the adult Norwegian population (72.8% women) filled at least one prescription of bupropion‐naltrexone, 0.91% used liraglutide (Saxenda; 74.2% women), and semaglutide without reimbursement was used by 0.68% (76.7% women). The prevalence increased with age, peaking in the age group 50 to 59 years, and decreased in older age groups. From 2017 to 2022, 2.8% of the adult residents initiated treatment with an anti‐obesity drug. The total sale of those drugs increased from 1.1 million euros in 2017 to 91.8 million euros in 2022.
Conclusions
The use of anti‐obesity drugs in Norway has increased substantially in recent years, especially among women aged 40 to 59 years. Changes in availability and reimbursement have influenced the use of these drugs in recent years.</description><identifier>ISSN: 1462-8902</identifier><identifier>EISSN: 1463-1326</identifier><identifier>DOI: 10.1111/dom.15515</identifier><identifier>PMID: 38419410</identifier><language>eng</language><publisher>Oxford, UK: Blackwell Publishing Ltd</publisher><subject>Adolescent ; Adult ; Adults ; Age groups ; Aged ; Anti-Obesity Agents - economics ; Anti-Obesity Agents - therapeutic use ; anti‐obesity drug ; Bupropion ; Bupropion - therapeutic use ; Cyclobutanes ; Drug Costs - statistics & numerical data ; Drug therapy ; Drug Utilization - statistics & numerical data ; Drug Utilization - trends ; Drugs ; Female ; Glucagon-Like Peptides - analogs & derivatives ; Glucagon-Like Peptides - therapeutic use ; Humans ; Liraglutide - therapeutic use ; Male ; Middle Aged ; Naltrexone ; Naltrexone - therapeutic use ; Norway - epidemiology ; Obesity ; Obesity - drug therapy ; Obesity - epidemiology ; obesity therapy ; observational study ; Orlistat - therapeutic use ; pharmaco‐epidemiology ; Prevalence ; Registries ; Reimbursement ; Rimonabant - therapeutic use ; Sibutramine ; Young Adult</subject><ispartof>Diabetes, obesity & metabolism, 2024-06, Vol.26 (6), p.2102-2110</ispartof><rights>2024 The Authors. published by John Wiley & Sons Ltd.</rights><rights>2024 The Authors. Diabetes, Obesity and Metabolism published by John Wiley & Sons Ltd.</rights><rights>2024. This article is published under http://creativecommons.org/licenses/by-nc-nd/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>info:eu-repo/semantics/openAccess</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4135-9dc5d6635ab20eb9b742cd0fc4aa44959a320cf74bd40431bfefa095f03a00243</citedby><cites>FETCH-LOGICAL-c4135-9dc5d6635ab20eb9b742cd0fc4aa44959a320cf74bd40431bfefa095f03a00243</cites><orcidid>0000-0002-3404-2060</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fdom.15515$$EPDF$$P50$$Gwiley$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fdom.15515$$EHTML$$P50$$Gwiley$$Hfree_for_read</linktohtml><link.rule.ids>230,314,776,780,881,1411,26544,27901,27902,45550,45551</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38419410$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ruiz, Paz Lopez‐Doriga</creatorcontrib><creatorcontrib>Karlstad, Øystein</creatorcontrib><creatorcontrib>Nøkleby, Kjersti</creatorcontrib><creatorcontrib>Slåtsve, Kristina</creatorcontrib><creatorcontrib>Gulseth, Hanne L.</creatorcontrib><creatorcontrib>Meyer, Haakon E.</creatorcontrib><creatorcontrib>Sveen, Kari Anne</creatorcontrib><creatorcontrib>Qvigstad, Elisabeth</creatorcontrib><creatorcontrib>Furu, Kari</creatorcontrib><title>Pharmacological treatment of obesity in adults in Norway 2004–2022</title><title>Diabetes, obesity & metabolism</title><addtitle>Diabetes Obes Metab</addtitle><description>Aims
To describe trends in the use of anti‐obesity drugs in Norway during the period 2004–2022.
Materials and Methods
We assessed the annual utilization of any available drug indicated for obesity recorded in the nationwide Norwegian Prescribed Drug Register for adults (age 18–79 years) from 1 January 2004 to 31 December 2022. Prevalence was stratified by sex and age group (18–29 years and 10‐year age groups thereafter). Additional analyses were performed in individuals initiating treatment with an anti‐obesity drug and on the cost of the anti‐obesity drugs since 2017.
Results
The prevalence of anti‐obesity drug use decreased from 2009, when sibutramine and rimonabant were withdrawn from the market, and increased again after the approval of bupropion‐naltrexone in 2017 and liraglutide in 2018. The use of the peripheral‐acting anti‐obesity drug orlistat decreased from 2004. In 2022, 1.04% of the adult Norwegian population (72.8% women) filled at least one prescription of bupropion‐naltrexone, 0.91% used liraglutide (Saxenda; 74.2% women), and semaglutide without reimbursement was used by 0.68% (76.7% women). The prevalence increased with age, peaking in the age group 50 to 59 years, and decreased in older age groups. From 2017 to 2022, 2.8% of the adult residents initiated treatment with an anti‐obesity drug. The total sale of those drugs increased from 1.1 million euros in 2017 to 91.8 million euros in 2022.
Conclusions
The use of anti‐obesity drugs in Norway has increased substantially in recent years, especially among women aged 40 to 59 years. Changes in availability and reimbursement have influenced the use of these drugs in recent years.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Adults</subject><subject>Age groups</subject><subject>Aged</subject><subject>Anti-Obesity Agents - economics</subject><subject>Anti-Obesity Agents - therapeutic use</subject><subject>anti‐obesity drug</subject><subject>Bupropion</subject><subject>Bupropion - therapeutic use</subject><subject>Cyclobutanes</subject><subject>Drug Costs - statistics & numerical data</subject><subject>Drug therapy</subject><subject>Drug Utilization - statistics & numerical data</subject><subject>Drug Utilization - trends</subject><subject>Drugs</subject><subject>Female</subject><subject>Glucagon-Like Peptides - analogs & derivatives</subject><subject>Glucagon-Like Peptides - therapeutic use</subject><subject>Humans</subject><subject>Liraglutide - therapeutic use</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Naltrexone</subject><subject>Naltrexone - therapeutic use</subject><subject>Norway - epidemiology</subject><subject>Obesity</subject><subject>Obesity - drug therapy</subject><subject>Obesity - epidemiology</subject><subject>obesity therapy</subject><subject>observational study</subject><subject>Orlistat - therapeutic use</subject><subject>pharmaco‐epidemiology</subject><subject>Prevalence</subject><subject>Registries</subject><subject>Reimbursement</subject><subject>Rimonabant - therapeutic use</subject><subject>Sibutramine</subject><subject>Young Adult</subject><issn>1462-8902</issn><issn>1463-1326</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>24P</sourceid><sourceid>EIF</sourceid><sourceid>3HK</sourceid><recordid>eNp1kLtOxDAQRS0E4rFQ8AMoEg0U2R2_krhEy1MClgJqy3EcCEpisBOhdPwDf8iX4N0ABRLTeIqjc8cXoX0MUxxmVthmijnHfA1tY5bQGFOSrK92EmcCyBba8f4ZABjN0k20RTOGBcOwjU7vnpRrlLa1fay0qqPOGdU1pu0iW0Y2N77qhqhqI1X0deeX2611b2qISLB9vn8QIGQXbZSq9mbv-52gh_Oz-_llfL24uJqfXMeaYcpjUWheJAnlKidgcpGnjOgCSs2UYkxwoSgBXaYsL1i4FOelKRUIXgJVAITRCYpGr3aV76pWttYpiSHjRIYeAhGQoxF5cfa1N76TTeW1qWvVGtt7SQSlLAGcQEAP_6DPtndt-ICkwHGacZqKQB3_ZFrvnSnli6sa5YaQuwzFMrQvV-0H9uDb2OeNKX7Jn7oDMBuBt6o2w_8mebq4GZVfRI-KiQ</recordid><startdate>202406</startdate><enddate>202406</enddate><creator>Ruiz, Paz Lopez‐Doriga</creator><creator>Karlstad, Øystein</creator><creator>Nøkleby, Kjersti</creator><creator>Slåtsve, Kristina</creator><creator>Gulseth, Hanne L.</creator><creator>Meyer, Haakon E.</creator><creator>Sveen, Kari Anne</creator><creator>Qvigstad, Elisabeth</creator><creator>Furu, Kari</creator><general>Blackwell Publishing Ltd</general><general>Wiley Subscription Services, Inc</general><scope>24P</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>7TK</scope><scope>H94</scope><scope>K9.</scope><scope>7X8</scope><scope>3HK</scope><orcidid>https://orcid.org/0000-0002-3404-2060</orcidid></search><sort><creationdate>202406</creationdate><title>Pharmacological treatment of obesity in adults in Norway 2004–2022</title><author>Ruiz, Paz Lopez‐Doriga ; Karlstad, Øystein ; Nøkleby, Kjersti ; Slåtsve, Kristina ; Gulseth, Hanne L. ; Meyer, Haakon E. ; Sveen, Kari Anne ; Qvigstad, Elisabeth ; Furu, Kari</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4135-9dc5d6635ab20eb9b742cd0fc4aa44959a320cf74bd40431bfefa095f03a00243</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Adults</topic><topic>Age groups</topic><topic>Aged</topic><topic>Anti-Obesity Agents - economics</topic><topic>Anti-Obesity Agents - therapeutic use</topic><topic>anti‐obesity drug</topic><topic>Bupropion</topic><topic>Bupropion - therapeutic use</topic><topic>Cyclobutanes</topic><topic>Drug Costs - statistics & numerical data</topic><topic>Drug therapy</topic><topic>Drug Utilization - statistics & numerical data</topic><topic>Drug Utilization - trends</topic><topic>Drugs</topic><topic>Female</topic><topic>Glucagon-Like Peptides - analogs & derivatives</topic><topic>Glucagon-Like Peptides - therapeutic use</topic><topic>Humans</topic><topic>Liraglutide - therapeutic use</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Naltrexone</topic><topic>Naltrexone - therapeutic use</topic><topic>Norway - epidemiology</topic><topic>Obesity</topic><topic>Obesity - drug therapy</topic><topic>Obesity - epidemiology</topic><topic>obesity therapy</topic><topic>observational study</topic><topic>Orlistat - therapeutic use</topic><topic>pharmaco‐epidemiology</topic><topic>Prevalence</topic><topic>Registries</topic><topic>Reimbursement</topic><topic>Rimonabant - therapeutic use</topic><topic>Sibutramine</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ruiz, Paz Lopez‐Doriga</creatorcontrib><creatorcontrib>Karlstad, Øystein</creatorcontrib><creatorcontrib>Nøkleby, Kjersti</creatorcontrib><creatorcontrib>Slåtsve, Kristina</creatorcontrib><creatorcontrib>Gulseth, Hanne L.</creatorcontrib><creatorcontrib>Meyer, Haakon E.</creatorcontrib><creatorcontrib>Sveen, Kari Anne</creatorcontrib><creatorcontrib>Qvigstad, Elisabeth</creatorcontrib><creatorcontrib>Furu, Kari</creatorcontrib><collection>Wiley Online Library Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><collection>NORA - Norwegian Open Research Archives</collection><jtitle>Diabetes, obesity & metabolism</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ruiz, Paz Lopez‐Doriga</au><au>Karlstad, Øystein</au><au>Nøkleby, Kjersti</au><au>Slåtsve, Kristina</au><au>Gulseth, Hanne L.</au><au>Meyer, Haakon E.</au><au>Sveen, Kari Anne</au><au>Qvigstad, Elisabeth</au><au>Furu, Kari</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Pharmacological treatment of obesity in adults in Norway 2004–2022</atitle><jtitle>Diabetes, obesity & metabolism</jtitle><addtitle>Diabetes Obes Metab</addtitle><date>2024-06</date><risdate>2024</risdate><volume>26</volume><issue>6</issue><spage>2102</spage><epage>2110</epage><pages>2102-2110</pages><issn>1462-8902</issn><eissn>1463-1326</eissn><abstract>Aims
To describe trends in the use of anti‐obesity drugs in Norway during the period 2004–2022.
Materials and Methods
We assessed the annual utilization of any available drug indicated for obesity recorded in the nationwide Norwegian Prescribed Drug Register for adults (age 18–79 years) from 1 January 2004 to 31 December 2022. Prevalence was stratified by sex and age group (18–29 years and 10‐year age groups thereafter). Additional analyses were performed in individuals initiating treatment with an anti‐obesity drug and on the cost of the anti‐obesity drugs since 2017.
Results
The prevalence of anti‐obesity drug use decreased from 2009, when sibutramine and rimonabant were withdrawn from the market, and increased again after the approval of bupropion‐naltrexone in 2017 and liraglutide in 2018. The use of the peripheral‐acting anti‐obesity drug orlistat decreased from 2004. In 2022, 1.04% of the adult Norwegian population (72.8% women) filled at least one prescription of bupropion‐naltrexone, 0.91% used liraglutide (Saxenda; 74.2% women), and semaglutide without reimbursement was used by 0.68% (76.7% women). The prevalence increased with age, peaking in the age group 50 to 59 years, and decreased in older age groups. From 2017 to 2022, 2.8% of the adult residents initiated treatment with an anti‐obesity drug. The total sale of those drugs increased from 1.1 million euros in 2017 to 91.8 million euros in 2022.
Conclusions
The use of anti‐obesity drugs in Norway has increased substantially in recent years, especially among women aged 40 to 59 years. Changes in availability and reimbursement have influenced the use of these drugs in recent years.</abstract><cop>Oxford, UK</cop><pub>Blackwell Publishing Ltd</pub><pmid>38419410</pmid><doi>10.1111/dom.15515</doi><tpages>9</tpages><orcidid>https://orcid.org/0000-0002-3404-2060</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1462-8902 |
| ispartof | Diabetes, obesity & metabolism, 2024-06, Vol.26 (6), p.2102-2110 |
| issn | 1462-8902 1463-1326 |
| language | eng |
| recordid | cdi_cristin_nora_10852_111243 |
| source | MEDLINE; NORA - Norwegian Open Research Archives; Wiley Online Library Journals Frontfile Complete |
| subjects | Adolescent Adult Adults Age groups Aged Anti-Obesity Agents - economics Anti-Obesity Agents - therapeutic use anti‐obesity drug Bupropion Bupropion - therapeutic use Cyclobutanes Drug Costs - statistics & numerical data Drug therapy Drug Utilization - statistics & numerical data Drug Utilization - trends Drugs Female Glucagon-Like Peptides - analogs & derivatives Glucagon-Like Peptides - therapeutic use Humans Liraglutide - therapeutic use Male Middle Aged Naltrexone Naltrexone - therapeutic use Norway - epidemiology Obesity Obesity - drug therapy Obesity - epidemiology obesity therapy observational study Orlistat - therapeutic use pharmaco‐epidemiology Prevalence Registries Reimbursement Rimonabant - therapeutic use Sibutramine Young Adult |
| title | Pharmacological treatment of obesity in adults in Norway 2004–2022 |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-31T12%3A08%3A13IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_crist&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Pharmacological%20treatment%20of%20obesity%20in%20adults%20in%20Norway%202004%E2%80%932022&rft.jtitle=Diabetes,%20obesity%20&%20metabolism&rft.au=Ruiz,%20Paz%20Lopez%E2%80%90Doriga&rft.date=2024-06&rft.volume=26&rft.issue=6&rft.spage=2102&rft.epage=2110&rft.pages=2102-2110&rft.issn=1462-8902&rft.eissn=1463-1326&rft_id=info:doi/10.1111/dom.15515&rft_dat=%3Cproquest_crist%3E2933460160%3C/proquest_crist%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3051785379&rft_id=info:pmid/38419410&rfr_iscdi=true |